Understanding Tysabri-Related PML: Diagnosis and Follow-Up in New York

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one is taking Tysabri and concerned about the risk of progressive multifocal leukoencephalopathy (PML), understanding the diagnostic process is crucial. The legacy of medical surveillance and adverse event reporting has long provided a framework for tracking such risks. This page explains how PML is diagnosed, monitored, and reported through the FDA Adverse Event Reporting System (FAERS), with a focus on New York data.

Tysabri and the Risk of Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information includes a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and Tysabri's mechanism of action—blocking lymphocyte migration into the central nervous system—is believed to create a permissive environment for JCV reactivation and spread. Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patient enrollment, medication guide review, and specially certified pharmacies and infusion centers (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

Clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive decline, visual loss, and speech difficulties. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via PCR. The timeline between Tysabri exposure and PML onset varies; cases have been reported after a few months to several years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). FDA adverse event reports for Tysabri frequently list fatigue, multiple sclerosis relapse, headache, gait disturbance, and cognitive disorder among the most common events (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically quantify PML incidence, they underscore the range of neurological symptoms that may overlap with or obscure early PML signs.

Legal Considerations and Statute of Limitations in New York

For patients who develop PML after Tysabri therapy, legal considerations may arise regarding the adequacy of warnings provided by the manufacturer. The boxed warning explicitly states that Tysabri increases PML risk and identifies known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may focus on whether prescribers and patients were sufficiently informed about the magnitude of risk, the need for regular monitoring, and the importance of early symptom recognition. The TOUCH program is designed to mitigate risk through controlled distribution and education, but its effectiveness in preventing PML or ensuring timely diagnosis may be contested in individual cases. In New York, the statute of limitations for personal injury claims related to Tysabri and PML is generally governed by state law. For medical malpractice or product liability actions, the time limit is typically three years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. Given that PML can develop insidiously over months, the discovery rule may be critical. Patients who experienced PML symptoms but were not diagnosed until later may need to establish when they knew or should have known that Tysabri caused their harm. The timeline between Tysabri exposure and documented PML diagnosis is therefore a key factual element in any legal claim. Attorney considerations for affected patients include gathering medical records documenting Tysabri treatment dates, anti-JCV antibody status, prior immunosuppressant use, and the clinical course of PML. Expert testimony may be needed to explain the mechanistic link between Tysabri and PML, as well as to assess whether the manufacturer's warnings were adequate. The presence of the boxed warning and TOUCH program requirements may be used by the defense to argue that risks were properly communicated. However, plaintiffs may argue that the warnings did not sufficiently emphasize the severity or likelihood of PML, or that monitoring recommendations were not followed. In summary, Tysabri-associated PML is a serious, often fatal condition with well-documented risk factors and a mandated risk management program. Patients in New York who develop PML after Tysabri therapy should be aware of the statute of limitations and the need to promptly consult legal counsel to preserve their rights. The interplay between clinical presentation, risk factor assessment, and timing of diagnosis will be central to both medical management and any subsequent legal action.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in New York?

In New York, the statute of limitations for personal injury claims related to Tysabri and PML is generally three years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. This discovery rule is critical because PML can develop insidiously over months.

What are the established risk factors for PML in Tysabri-treated patients?

Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.